期刊文献+

LC-MS测定人血浆中匹伐他汀浓度及其应用 被引量:3

Determination of the Concentration of Pitavastatin in Human Plasma by LC-MS and Subsequent Application to a Clinical Study
原文传递
导出
摘要 目的建立LC-MS测定人血浆中匹伐他汀的浓度。方法采用Shim-pack C18色谱柱,流动相A为甲醇,流动相B为含0.025%氨水和0.05mmol·L-1醋酸铵的水溶液,采用梯度洗脱方式。质谱检测方式:SIM。以瑞舒伐他汀为内标,血浆样品用乙酸乙酯提取浓缩检测,进行LC-MS分析。结果匹伐他汀在0.2~200.0ng·mL-1内线性关系良好(r=0.9999);平均提取回收率均为86.28%;日内日间RSD均小于12%。结论本方法快速、简捷、准确,适用于匹伐他汀的临床药动学研究和血药浓度监测。 OBJECTIVE To establish an LC-MS method for the determination of pitavastatin in the human plasma.METHODS Pitavastatin and internal standard(IS,rosuvastatin) were separated on a Shim-pack C18 column.The mobile phase consisted of methanol/water(A/B) with 0.025% aqueous ammonia and 0.05 mmol·L^-1 ammonium acetate.Gradient elution mode was established.The samples were extracted with ethyl acetate and determined by LC-MS with selected ion monitoring(SIM) mode.RESULTS The linear calibration curve was obtained in the concentration range of 0.2-200.0 ng·mL^-1(r=0.999 9),the average extraction recovery was 86.28% and the RSD of inter-and intra-day were less than 12%.CONCLUSION The developed analytical method was proved accurate,rapid,convenient,and suitable for the determination of pitavastatin in the human plasma and pharmacokinetic studies of pitavastatin.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2010年第1期62-65,共4页 Chinese Journal of Modern Applied Pharmacy
基金 江西省重大科技支撑计划重点项目(2007BS12804)
关键词 匹伐他汀 液相色谱-质谱联用 血药浓度 pitavastatin LC-MS plasma drug concentration
  • 相关文献

参考文献10

  • 1KAJINAMI K, TAKEKOSHI N, SAITO Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor [J]. Cardiovasc Drug Rev, 2003, 21(3): 199-215.
  • 2LEE S H, CHUNG N, KWAN J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholestermia [J]. Clin Ther, 2007, 29 (11): 2365-2373.
  • 3MUKHTAR R Y, REID J, RECKLESS J P. Pitavastatin [J]. Int J Clin Pract, 2005, 59 (2): 239-252.
  • 4SAKABE K, FUKUDA N, FUKUDA Y, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function [J]. Int J Cardiol, 2008, 125 (1): 136-138.
  • 5DI B, SUM X, YU F, et al. Solid-phase extraction and liquid chromatography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clinical pharmacokinetic studies [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2008, 868(1-2): 95-101.
  • 6LV H, SUN J G, WANG G J, et al. Determination of pitavastatin in human plasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteers [J]. Clin Chim Acta, 2007, 386 (1-2): 25-30.
  • 7IEIRI I, SUWANNAKUL S, MAEDA K, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers [J]. Clin Pharmacol Ther, 2007, 82 (5): 541-547.
  • 8NISHIZATO Y, IEIRI I, SUZUKI H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes condequences for pravastatin pharmacokinetics [J]. Clin Pharmcol Ther, 2003, 73 (6): 554-565.
  • 9TIRONA R G. Ethnic differences in statin disposition [J]. Clin Pharmacol Ther, 2005, 78 (4): 330-341.
  • 10CHUNG J Y, CHO J Y, YU KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers [J]. Clin Pharmacol Ther, 2005, 78 (4): 342-350.

同被引文献25

  • 1何笑荣,邹定,姜文清,马捷,李金娥.降血脂新药匹伐他汀[J].中国新药杂志,2005,14(4):483-487. 被引量:32
  • 2Suzuki M,Iwasaki H,Fujikawa Y,et al.Bioorg Med Chem,2001,9(10):2727.
  • 3Lv H,Sun J G,Wang G J,et al.Clin Chim Acta,2007,386:25.
  • 4Shentu J Z,Xu X,Liu J,et al.Chromatographia,2009,69:1041.
  • 5Di B,Su M X,Yu F,et al.J Chromatogr B,2008,868:95.
  • 6OJHA Ashwini,GUTTIKAR Swati,VAYEDA Chintan,PADH Harish.高效液相色谱-荧光检测法测定人血浆中的匹伐他汀(英文)[J].色谱,2007,25(5):715-718. 被引量:8
  • 7Niemi M,Backman JT,Kajosaari LI,et al.Poly-morphic organicanion transporting polypept de 1B1is a major determinant of repaglinide pharmacokinet-ics[].Clinical Pharmacology and Therapeutics.2005
  • 8CHUNG JY,CHO JY,YU KS,et al.Effect of OATP1B1 (SLCO1B1)variant alleles on the pharmacokinetics of pitavasta-tin in healthy volunteers[].Clinical Pharmacology and Therapeutics.2005
  • 9OWENS DR.Repaglinide-prandial glucose regulator:a newclass of oral antidiabetic drugs[].Diabetic Medicine.1999
  • 10SHITARA Y,ITOH T,SATO H,et al.Inhibition of ransportermediated hepatic up take as a mechanism for drug-drug interac-tion between cerivastatin and cyclosporin A[].Journal of Pharmacology and Experimental Therapeutics.2003

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部